分析长春西汀联合依达拉奉治疗急性脑梗死的疗效及对血浆炎性因子水平的影响

目的分析长春西汀联合依达拉奉治疗急性脑梗死的疗效及对血浆炎性因子水平的影响。方法106例急性脑梗死患者,以随机法将其分为对照组与研究组,各53例。对照组单纯性给予长春西汀治疗,研究组给予长春西汀联合依达拉奉治疗。比较两组治疗效果、美国国立卫生研究院卒中量表(NIHSS)评分、日常生活活动能力量表(Barthel)指数、血浆炎性因子超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-8(IL-8)]水平。结果研究组治疗总有效率94.34%高于对照组的77.36%,差异具有统计学意义(P<0.05)。治疗后,研究组患者的NIHSS评分(8.68±1.73)分、Barthel指数评分(77.93±9.22)分均优于对照组的(11.50±1.90)、(68.18±8.98)分,差异具有统计学意义(P<0.05)。研究组hs-CRP、TNF-α、IL-8水平分别为(14.94±5.77)mg/L、(74.30±14.88)μg/L、(14.80±5.14)μmol/L均低于对照组的(17.79±6.42)mg/L、(91.45±16.31)μg/L、(21.44±4.16)μmol/L,差异均具有统计学意义(P<0.05)。结论长春西汀联合依达拉奉治疗方案的实施有效提高了急性脑梗死病症的治疗效果,缓解其神经功能缺损情况,提高日常生活能力,改善血浆炎性因子水平,值得推广。

Analysis of efficacy of vinpocetine combined with edaravone on acute cerebral infarction and its influence on plasma inflammatory factors

Objective To discuss the efficacy of vinpocetine combined with edaravone on acute cerebral infarction and its influence on plasma inflammatory factors.Methods A total of 106 patients with acute cerebral infarction were randomly divided into control group and research group,with 53 cases in each group.The control group was treated by vinpocetine,and the research group was treated by vinpocetine combined with edaravone.The therapeutic effect,National Institutes of Health stroke scale(NIHSS),Barthel index,plasma inflammatory factorshypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-8(IL-8)]were compared between the two groups.Results The total effective rate of treatment 94.34%in the research group was higher than 77.36% in the control group,and the difference was statistically significant(P<0.05).After treatment,the NIHSS score(8.68±1.73)points and Barthel index score(77.93±9.22)points in the research group was better than(11.50±1.90)and(68.18±8.98)points in the control group.Their difference was statistically significant(P<0.05).The levels of hs-CRP,TNF-αand IL-8 were(14.94±5.77)mg/L,(74.30±14.88)μg/L and(14.80±5.14)μmol/L respectively in the research group,which was lower than(17.79±6.42)mg/L,(91.45±16.31)μg/L and(21.44±4.16)μmol/L in the control group,and their difference was statistically signficant(P<0.05).Conclusion Vinpocetine combined with edaravone can effectively improve the therapeutic effect of acute cerebral infarction,relieve the neurological deficit,improve the ability of daily life,and improve the level of plasma inflammatory factors,which is worth popularizing.